Wollenberg, A., Blauvelt, A., Guttman‐Yassky, E., Worm, M., Lynde, C., Lacour, J., Spelman, L., Katoh, N., Saeki, H., Poulin, Y., Lesiak, A., Kircik, L., Cho, S., Herranz, P., Cork, M., Peris, K., Steffensen, L., Bang, B., Kuznetsova, A., Jensen, T., Østerdal, M., Simpson, E., & , (2021). tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*. British journal of dermatology, 184, 437–449. http://access.bl.uk/ark:/81055/vdc_100172209698.0x00001f